A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer

ClinicalTrials.gov ID: NCT01589419

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01589419. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Phase 1b Study of the Safety and Tolerability of Veliparib in Combination With Capecitabine and Radiation in Subjects With Locally Advanced Rectal Cancer (LARC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

An open-label, Phase 1b, dose escalation study evaluating the safety and tolerability of the PARP inhibitor Veliparib in combination with capecitabine and radiation in subjects with locally advanced rectal cancer (LARC).

Study identification

NCT ID: NCT01589419
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Enrollment: 32 participants

Conditions and interventions

Conditions

Locally Advanced Rectal Cancer

Interventions

veliparib Drug
capecitabine Drug
radiation Radiation

Drug · Radiation

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2012 (Type not available)
Primary completion: Jan 2015 (Actual)
Completion: Jan 2015 (Actual)
Last update posted: Nov 20, 2017

2012 – 2015

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
Site Reference ID/Investigator# 99095	Scottsdale	Arizona	85258	—
Site Reference ID/Investigator# 68044	Chicago	Illinois	60611	—
Site Reference ID/Investigator# 112395	Goshen	Indiana	46526	—
Site Reference ID/Investigator# 68045	Durham	North Carolina	27710	—
Site Reference ID/Investigator# 68043	Madison	Wisconsin	53792	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01589419, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 20, 2017 · Synced Nov 15, 2026